Enrique Gómez Gómez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6584214/publications.pdf

Version: 2024-02-01

567144 642610 36 587 15 23 g-index citations h-index papers 37 37 37 869 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer. World Journal of Urology, 2022, 40, 2195-2203.	1.2	4
2	Telomere-based risk models for the early diagnosis of clinically significant prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 88-95.	2.0	1
3	Clinical, Cellular, and Molecular Evidence of the Additive Antitumor Effects of Biguanides and Statins in Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e696-e710.	1.8	19
4	Influence of Obesity in the miRNome: miR-4454, a Key Regulator of Insulin Response Via Splicing Modulation in Prostate. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e469-e484.	1.8	20
5	Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer and Prostatic Diseases, 2021, 24, 567-574.	2.0	28
6	Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance. Korean Journal of Radiology, 2021, 22, 559.	1.5	3
7	Prospective study of diagnostic accuracy in the detection of highâ€grade prostate cancer in biopsyâ€naìve patients with clinical suspicion of prostate cancer who underwent the Select MDx test. Prostate, 2021, 81, 857-865.	1.2	9
8	Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?. Diagnostics, 2021, 11, 1335.	1.3	8
9	Comparative Cytotoxic Activity of Hydroxytyrosol and Its Semisynthetic Lipophilic Derivatives in Prostate Cancer Cells. Antioxidants, 2021, 10, 1348.	2.2	10
10	Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer. EBioMedicine, 2020, 51, 102547.	2.7	71
11	Noninvasive biomarkers to guide intervention: toward personalized patient management in prostate cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 383-400.	0.4	4
12	Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer. Journal of Clinical Medicine, 2020, 9, 1703.	1.0	5
13	A Single-Center Experience With Third and Fourth Kidney Transplants and Second Kidney Transplant After Pancreas-Kidney Transplant: Surgical Aspects and Outcomes. Experimental and Clinical Transplantation, 2020, 18, 149-152.	0.2	0
14	Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases, 2019, 22, 84-90.	2.0	17
15	Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer. Translational Research, 2019, 212, 89-103.	2.2	47
16	Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer. Journal of Clinical Medicine, 2019, 8, 1400.	1.0	16
17	Expression of miRâ€100 and miRâ€138 as prognostic biomarkers in nonâ€muscleâ€invasive bladder cancer. Apmis, 2019, 127, 545-553.	0.9	20
18	CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer. British Journal of Cancer, 2019, 120, 1120-1128.	2.9	25

#	Article	IF	Citations
19	Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL. BMJ Open, 2019, 9, e031032.	0.8	6
20	Clinical association of metabolic syndrome, Câ€reactive protein and testosterone levels with clinically significant prostate cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 934-942.	1.6	19
21	New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience. Urology, 2018, 121, 198-199.	0.5	3
22	Plasma ghrelin Oâ€acyltransferase (GOAT) enzyme levels: A novel nonâ€invasive diagnosis tool for patients with significant prostate cancer. Journal of Cellular and Molecular Medicine, 2018, 22, 5688-5697.	1.6	17
23	Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer. Prostate, 2017, 77, 1499-1511.	1.2	24
24	The oncogenic role of the spliced somatostatin receptor sst5TMD4 variant in prostate cancer. FASEB Journal, 2017, 31, 4682-4696.	0.2	41
25	European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance. Urology, 2017, 102, 85-91.	0.5	16
26	The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness. Molecular Cancer, 2017, 16, 146.	7.9	41
27	The management of active surveillance in prostate cancer: validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry. Oncotarget, 2017, 8, 108451-108462.	0.8	5
28	Partial thrombosis of the corpus cavernosum: should we dig deeper into coagulopathy disorders?. Andrologia, 2016, 48, 1313-1316.	1.0	2
29	Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker. Cancer Letters, 2016, 383, 125-134.	3.2	30
30	A tertiary experience of ileal–ureter substitution: Contemporary indications and outcomes. Scandinavian Journal of Urology, 2016, 50, 192-199.	0.6	18
31	Impacto de la visión 3D sobre la carga mental y el rendimiento laparoscópico en individuos sin experiencia. Actas Urológicas Espa±olas, 2015, 39, 229-235.	0.3	23
32	Perineostomy: the last oportunity. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2015, 41, 91-100.	0.7	8
33	Evaluación del dolor y factores asociados en pacientes sometidos a biopsia de próstata. Actas Urológicas Españolas, 2015, 39, 414-419.	0.3	12
34	Palliative Surgery for Rare Cases of Anterior Urethral Metastasis in Prostate Cancer. Case Reports in Urology, 2014, 2014, 1-4.	0.1	3
35	Hemangioma cavernoso intraescrotal; una enfermedad poco frecuente. Revista Internacional De AndrologÃa, 2014, 12, 32-36.	0.1	1
36	Long-term Allograft Survival After Kidney Transplantation. Transplantation Proceedings, 2013, 45, 3599-3602.	0.3	11